You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a GABA Enzyme for Biosensor Applications
SBC: Pinnacle Technology, Inc. Topic: 101Abstract As the most important inhibitory neurotransmitter in the braina detailed understanding of the implications of gamma aminobutyric acidGABArelease remains elusiveThe measurement of GABA concentrations is a difficult processMicrodialysis is the current standard for GABA sampling in the brains of freely moving animalsbut suffers from low temporal resolution and the need for labor intensive an ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a protein drug for pancreatic cancer treatment
SBC: ProDa BioTech L.L.C. Topic: NCIAbstract Pancreatic cancers are devastating diseases with five year survival rate less than Currently there is no effective treatment for advanced disease One major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal response Evidence suggests that cancer associated pancreatic stellate cells CAPaSC produce the stromal collagen The ECM laid down by CAPaSC is c ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
IND enabling studies for a personalized immunotherapy for triple negative breast cancer
SBC: METACLIPSE THERAPEUTICS CORP Topic: NCIAbstract The worldwide incidence of breast cancer ismillionTriple negative breast cancersTNBCaccount forof total breast cancer casesworldwideAnnuallyovernew cases of TNBC are diagnosed in the US aloneThe treatment options for TNBC patients are limitedTriple negative breast cancerTNBCincludes breast cancers that lack estrogen receptorprogesterone receptorand HERproteinsLack of known targets and pat ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Monoclonal lamprey VLR antibodies specific for mucin type O linked glycan core structures
SBC: Novab, Inc. Topic: 300PROJECT SUMMARY We will develop and commercialize to the research community a new class of glycan specific binding reagents that incorporate the recognition function of variable lymphocyte receptors VLRs the antigen receptors of the adaptive immune system of jawless vertebrates lamprey and hagfish Such reagents are essential to detecting localizing quantifying and establishing biological ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
RealConsent: A web-based program to reduce college women's risk of sexual violence by targeting alcohol use, communication and consent, and building supportive networks.
SBC: BEHAVIORAL SCIENCE TECHNOLOGIES LLC Topic: 400Sexual violenceSVexperienced by women on college campuses is a serious public health problem that has garnered a national responseCampus climate surveys show that approximately one in five college women experience sexual violenceFederal regulations now mandate implementation of educational prevention programs for new students of institutions of higher educationIHEsBest practices for sexual violenc ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Blood biopsy test for pan cancer mutations with error checking probes
SBC: GENETAG TECHNOLOGY, INC Topic: 102Blood biopsy test for pan cancer mutations with error checking probes Confidential PI Shafer David A PhD PROJECT SUMMARY GeneTAG Technology www genetagtech com has developed a series of molecular diagnostic assays for cancer and infectious diseases based on DNA amplification and proprietary detection methods Our primary system internal DDS iDDS probes comprises two interacting component ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Advanced therapeutic for Parkinson's Disease
SBC: Inhibikase Therapeutics, Inc. Topic: 105Parkinson s DiseasePDis a progressive neurodegenerative disorder that affectsmillion patient in the U Sannually andtomillion people worldwidePD is characterized by disorders of movementwhich are caused by the progressive loss of dopamine neurons in the substantia nigra pars compactaSNpcand autonomic dysfunctionanxietydepressionsleep disorders and cognitive impairment that are due to the degenerati ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Prodrug treatment for CML
SBC: Inhibikase Therapeutics, Inc. Topic: 102Inhibikase Therapeutics is a clinical stage bio pharmaceutical company that has developed a novel prodrug formulation for the popular anticancer agent Gleevec Gleevec treatment is commonly accompanied by significant burdensome gastrointestinal side effects that erode therapy success due to poor patient compliance Inhibikaseandapos s prodrug of Gleevec completely blunts these gastrointestina ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Chemo-enzymatic synthesis of nucleotide sugar libraries and therapy-relevant derivatives
SBC: CHEMILY, LLC Topic: 300Glycans and glycoconjugates are widespread in nature and play pivotal roles in cell cell recognitioncell differentiationand immunological responsesMost glycans and glycosylation reactions require nucleotide sugars as their essential building blocksThereforethe commercial availability of nucleotide sugars will determine future opportunities for carbohydrate based innovationsjust as the availability ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Human Neural Cell Exosomes as a therapeutic treatment for stroke
SBC: ARUNA BIO, INC. Topic: 105Project Summary More than drugs have failed in stroke clinical trials an unprecedented rate thought to be attributed to two major factors most therapeutics focus on a single secondary injury mechanism and testing in rodent models alone may not be adequate for predicting which treatment is going to be successful We will combine two unique enabling technologies to address these caveats ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health